The Freeman

DOH suspends dengue vaccinatio­n

-

MANILA — The Department of Health yesterday has placed the dengue vaccinatio­n program on hold following the analysis that the dengue vaccines used by the government pose risk to people without prior infection.

“In the light of this new analysis, the DOH will place the dengue vaccinatio­n on hold while review and consultati­on is ongoing with experts, key stakeholde­rs and the World Health Organizati­on,” Secretary Francisco Duque III said.

Sanofi Pasteur, the manufactur­er of dengue vaccine Dengvaxia, on December 29 revealed that the vaccine poses risks to those who were not infected by dengue virus before.

“The analysis confirmed that Dengvaxia provides persistent protective benefit against dengue fever in those who had prior infection. For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccinatio­n upon a subsequent dengue infection,” Sanofi said in a statement.

Duque advised the public not to panic as there is currently no reported case of severe infection among those who received the vaccine.

He also said that the department is still clarifying with Sanofi on what constitute­s a “severe disease.”

In 2016, the DOH launched the dengue vaccinatio­n initiative in Regions III, IV-A and National Capital Region—the three highly endemic regions. Over 700,000 individual­s received at least one dose of the vaccine.

DOH posted on its website that the dengue vaccine helps protect children against dengue caused by dengue virus serotypes 1, 2, 3 and 4.

The immunizati­on program is in line with the recommenda­tion of the WHO.

Duque assured that the people who received dengue vaccine, whether previously infected or not, will still get a 30-month protection from the virus from first dose.

When asked if the DOH will take legal action against Sanofi, Duque said that the department will still have to review the documents and analyze all circumstan­ces surroundin­g the issue of Dengvaxia.

“We need to go back quite a long way to put the facts together, the data together. And until that is available, we cannot answer your question with definitive response,” the health secretary said.

 ??  ??
 ?? PHILSTAR.COM FILE PHOTO ?? Sanofi Pasteur, the manufactur­er of dengue vaccine Dengvaxia, on December 29 revealed that the vaccine poses risks to those who were not infected by dengue virus before.
PHILSTAR.COM FILE PHOTO Sanofi Pasteur, the manufactur­er of dengue vaccine Dengvaxia, on December 29 revealed that the vaccine poses risks to those who were not infected by dengue virus before.

Newspapers in English

Newspapers from Philippines